Here are the top health stories for the day:
Paying stipend to PG medical students is statutory obligation of medical college: Madras HC
Stating that the stipend paid to the postgraduate medical students cannot be adjusted against the fees payable by the students, the Madras High Court bench recently held that the stipend is a statutory right of a postgraduate medical student working in the institute during the course.
“The payment of stipend for the work done by the PG medical students is a statutory obligation of the medical college. At the same time, it is the right of the students to receive stipends,” the first bench of Chief Justice Sanjay Vijaykumar Gangapurwala and Justice P D Audikesavalu observed.
This observation was made by the Court while considering the appeals made by two Puducherry-based private medical colleges- Mahatma Gandhi Medical College and Research Institute and Aarupadai Veedu Medical College Hospital.
For more details, check out the link given below:
Paying Stipend To PG Medical Students Is Statutory Obligation Of Medical College: Madras HC
NMC says No to physical mode, directs states to arrange online NEET PG counselling for all rounds including stray vacancy round in private medical colleges
With an aim to put an end to the issue of seat blocking in medical colleges, the Postgraduate Medical Education Board (PGMEB) of the National Medical Commission (NMC) has clarified that the counselling agencies in the State and the Centre will fill up seats in all medical institutes through online counselling.
Clarifying that the mode of counselling will be online even for the stray vacany round in Private Medical Colleges from this academic year, NMC PG Board has further mentioned that no college/institute should conduct the counselling, including the stray vacancy round, in physical mode.
For more details, check out the link given below:
Hetero lab gets CDSCO panel nod to study Pregabalin, Polmacoxib FDC tablet
The drug major Hetero Labs has got approval from the Subject Expert Committee (SEC) functional under Central Drug Standard Control Organization (CDSCO) to conduct a bioequivalence (BE) study and Phase III clinical trial of fixed-dose combination (FDC) pregabalin extended released 82.5mg plus polmacoxib 2mg tablet for treating moderate acute, chronic or neuropathic pain.
For more details, check out the link given below:
Hetero Lab Gets CDSCO Panel Nod To Study Pregabalin, Polmacoxib FDC Tablet
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.